You are here

Bioinspired Agent Kills Drug-Resistant Bacteria

Scientists develop treatment based on enzymes produced by human immune system

Researchers in Ireland have developed a bioinspired antimicrobial treatment that can rapidly kill drug-resistant bacteria. The treatment consists of iodo-thiocyanate complexes, which are inspired by enzymes and reactive molecules produced by the human immune system.

“The rise of ‘superbugs’ leaves the clinical community with a rapidly dwindling number of options to treat infectious disease and to prevent the spread of resistant bacteria in, for example, hospital settings,” said the study’s co-corresponding author, Professor Vincent O’Flaherty of the National University of Ireland Galway. The study was published in Frontiers in Microbiology.

Hospital-acquired infections are a major concern for elderly or infirm patients. When the infection is antibiotic-resistant, serious illness or death can result. Bacterial contamination can occur on medical devices, such as catheters, which are embedded in patients. Bacteria tend to aggregate on these implants and form slimy layers called biofilms, and biofilms can also form on chronic wounds, impairing wound-healing. Biofilms are particularly resistant to decontamination strategies.

With this in mind, the researchers set out to develop an effective antibacterial treatment, drawing their inspiration from naturally occurring peroxidase enzymes that play a role in immune defense against bacterial infections. Peroxidases can produce highly reactive oxidized molecules in the presence of hydrogen peroxide. Naturally present in bodily secretions, such as saliva, breast milk, and tears, these highly reactive substances can damage bacterial cells, resulting in their death.

However, enzymes are expensive and impractical to produce in the quantities required for a widely useable antibacterial treatment. Therefore, the researchers came up with an enzyme-free system consisting of hydrogen peroxide and two oxidizable substances, iodide and thiocynate. These iodo-thiocyanate complexes produce highly reactive antimicrobial substances without a peroxidase enzyme.

The team tested the ability of the complexes to kill a variety of bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant strain. To do this, they treated the bacteria in cell suspensions, where the cells float freely, or in biofilms. They also tested whether the bacteria became resistant to the complexes by incubating them with small doses over time.

The complexes caused rapid bacterial death in all of the tested strains, in some instances killing the bacteria within 30 seconds, even in small doses. They were able to kill both free-floating bacteria and those in biofilms, suggesting that they could be used for decontamination in a variety of situations. The complexes were also effective against MRSA, and the tested bacteria did not develop resistance over time.

Antibiotics often work by targeting a specific site in a bacterium. By including two oxidizable substances, the complexes produce a cocktail of antimicrobial molecules, damaging multiple bacterial sites simultaneously. This means that bacteria are unlikely to develop resistance to the complexes, according to the researchers.

The team hopes that the complexes could be applied as a disinfectant or even used to directly treat infected wounds.

“We will need to assess the safety and suitability of the complexes for use in or on humans,” O’Flaherty said. “We also need to develop delivery systems to deploy the treatment in a variety of settings that are currently affected by antibiotic-resistant bacteria.”

The list of potential applications includes presurgery skin washes; the disinfection of hospital surfaces and instruments; wound care; the treatment of ulcers; and the decontamination of medical devices.

Source: EurekAlert; May 2, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug